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1. Introduction 
Incubation of immature rythroid cells with 
inhibitors of heine synthesis, e.g., INH, and trans- 
ferrin-bound S9Fe results in iron accumulation i
various non-heine compartments including mitochon- 
dria [1-3]. Recently we isolated S9Fe-labeled 
mitochondria from reticulocytes preincubated with 
INH and S9Fe-transferrin. Reticulocyte lysate was 
able to mobilize iron from the mitochondria and this 
iron release was significantly stimulated by pyridoxal- 
5-phosphate [4]. 
In experiments presented here we observed that 
the addition of pyridoxal-5-phosphate or pyridoxal to 
S9Fe-loaded reticulocytes incubated with INH to 
block S9Fe utilization for heine synthesis caused the 
release of a considerable amount of radioiron from 
the cells. We demonstrated that this mobilization was 
due to the presence of a hydrazone formed from 
INH and pyridoxal or pyridoxal-5-phosphate. More- 
over, pyridoxal isonicotinoyl hydrazone was shown 
to form a complex (chelate) with iron in the solution. 
2. Materials and methods 
2.1. Chemicals 
INH was obtained from Spofa, Prague, pyridoxal 
Abbreviations: INH, isonicotinic acid hydrazide; PIH, pyridoxal 
isonicotinoyl hydrazone; Tris, Tris-fhydroxymethyl)amino- 
methane 
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hydrochloride and pyridoxal-5-phosphate from 
Merck, Darmstadt. Desferrioxamine was kindly 
provided by Ciba-Geigy, Basel. S9Fe-citrate 
(10 mCi/mg Fe) w~s purchased from the Zentral- 
institut ffir Kemforschung, Dresden. Incubation 
medium [5], which is similar to M 199, was obtained 
from the Institute of Sera and Vaccines, Prague. 
2.2. Preparation of  pyridoxal isonicotinoyl hydrazone 
{PIH) and PIH-iron complex 
Pyridoxal isonicotinoyl hydrazone was prepared 
in good yield by mixing together in equimolar 
quantities nearly saturated solutions of INH and 
pyridoxal, both in 0.1 M sodium acetate buffer 
(pH 4.5) and heating the mixture for 2-3 min at 
100°C. The relatively insoluble condensation product 
was filtered from the cooled solution, washed with 
water and dried. The hydrazone iswell soluble in 
dilute mineral acids and when adjusted to pH 7.4 it 
does not precipitate at concentrations of approx. 
5 mM or less. 
A complex of pyridoxal isonicotinoyl hydrazone 
with iron was obtained by mixing together freshly 
prepared solutions of PIH (5 raM, in 50 mM Tris, 
pH 7.4) with 3 mM ferric citrate (1 mol Fe 3+ : 10 tool 
citrate, pH 7.4). The dark red-brown precipitate, 
which was formed immediately after mixing both 
solutions, was filtered, thoroughly washed with 
water and dried. Before addition to the incubation 
mixture, PIH-Fe was mixed with a buffered salt solu- 
tion.(see below), dissolved by adding a small volume 
of 0.15 M HC1 and adjusted to pH 7A with NaOH. 
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2.3. Retieulocyte preparation and incubation 
Reticulocyteswere obtained from phenylhydrazine- 
treated rabbits [6] and washed prior to use as in [1]. 
S9Fe-labeled rabbit plasma was prepared as in [2]. 
Basic experimental design was similar to that in [1 ] 
with certain modifications. Reticulocytes were pre- 
incubated with INH (10 mM) and S9Fe-labeled rabbit 
plasma for 60 rain and thoroughly washed using the 
procedure in [1]. After this treatment radioiron 
accumulates in mitochondria (40-50% total cellular 
radioiron), in a low molecular weight fraction 
(25-30%) and ferritin (10-15%) and only the 
remaining 15-10% total cellular S9Fe is found in 
hemoglobin [2]. In the second phase of the experi- 
ment, SgFe-labeled reticulocytes (approx. 20% 
suspension) were reincubated in a buffered salt solu- 
tion [7] in a humidified atmosphere at 37°C in plastic 
tubes. The final volume of  the incubation mixture 
was 1 ml. The volume of incubated reticulocytes was 
calculated from the packed cell volume determined 
by the microhematocrit method. At indicated time 
intervals the tubes were transferred to an ice-bath and 
the cells and supernatant solution of each sample 
were separated by centrifugation at 1500 × g for 
10 min at 4°C. Cells were washed twice with cold 
saline. The radioactivity was counted [1 ] in both 
reticulocytes and in an aliquot of the supernatant and 
the percentage of iron mobilization from reticulocytes 
was calculated. 
The degree of hemolysis during reincubation was 
monitored by measuring A s4s of an aliquot of the 
supernatant to which KCN was added [8]. Those 
experiments in which cyanmethemoglobin was 
detected in the supernatant were not taken into con- 
sideration. 
2.4. A naly tical methods 
Specific activity of heme and the % total cellular 
radioiron in heme were determined as in [1 ]. Spectra 
were recorded using a Unicam SP-1 700 spectro- 
photometer.  
3. Results and discussion 
During 120 min reincubation of S9Fe-labeled 
reticulocytes in Hanks' solution, a maximum of 1.5% 
radioiron was released from the cells (table 1). Since 
Table 1 
Effect of pyridoxal-5-phosphate or pyridoxal on iron release from radioiron-loaded reticulocytes reincubated without or 
with INH (10 mM) 
Exp. Additions % Iron release from sgFe-reticulocytes 
Incubation time (min) 
15 30 60 120 
% SgFe utilized for heme a
synthesis during 
120 min reincubation 
Nil (control) 1.2 
INH 0.9 
Pyridoxal-5-phosphate (0.1mM) 1.0 
Pyridoxal-5-phosphate (1.0mM) 1.7 
INH + pyridoxal-5-phosphate (0.1 mM) 1.3 
INH + pyridoxal-5-phosphate (1.0 mM) 3.5 
1.2 1.4 1.5 77.2 
1.3 1.3 1.3 30.0 
1.7 1.8 2.6 79.1 
1.8 2.4 3.8 83.6 
1.6 2.7 5.2 35.6 
5.8 9.2 20.0 42.5 
INH 1.2 1.1 1.1 1.1 28.1 
Pyridoxal (0.1 mM) 2.2 2.8 2.9 3.0 73.1 
Pyridoxal (1.0 mM) 3.6 4.3 8.0 8.6 73.4 
INH + pyridoxal (0.1 mM) 9.3 17.1 24.9 30.7 24.1 
INH + pyridoxal (1.0 mM) 27.2 50.0 72.4 77.7 15.1 
a 
After 120 min reincubation of reticulocytes, [ SgFe]heme radioactivity was determined [1] and expressed as a % 59Fe-radio- 
activity found in re ticulocytes (= 100%) prior to the second incubation 
The results are the means of duplicate samples; the differences between duplicates did not exceed 5%. In both experiments after 
60 min preincubation with INH and sgFe-labeled plasma, heme radioactivity represented 15% of total cellular sgFe 
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the presence ofradioiron in the supernatant is not due 
to cell lysis (see section 2), it seems probable that 
radioiron here represents recycling of iron attached 
to transferrin molecules which have been released 
from reticulocytes after donating none or only one 
of their iron atoms [9]. 
INH, although it had been shown to form stable 
complexes with metals [10], did not enhance iron 
release from S9Fe-labeled reticulocytes. Modest, 
though significant, stimulation of iron mobilization 
from reticulocytes was observed after addition of 
pyridoxal-5-phosphate or pyridoxal. INH presence 
during reincubation considerably enhanced the effect 
of both compounds (table 1). Similar results were 
obtained in 5 additional experiments. The more pro- 
found effect ofpyridoxal on iron mobilization from 
reticulocytes may be due either to an easier perme- 
ability of red-cell membrane for pyridoxal than for 
pyridoxal-5-phosphate [ 11] and/or to the fact that 
pyridoxal-5-phosphate [ 12], but not pyridoxal, 
partially restores the rate of heme synthesis reduced 
by INH (table 1). 
One possible explanation for these observations i  
that INH blocks the utilization of intracellular non- 
heme iron for heme synthesis and thus renders intra- 
cellular S9Fe available for chelation either by each 
pyridoxal compound alone [13] or by a Schiff base 
formed from pyridoxal compounds and intracellular 
amino acids [14,15]. However, when INH was 
replaced by other heme synthesis inhibitors, such as 
5 mM penicillamine [12] or 20 mM levulinic acid 
[ 16], the amount of iron mobilized from reticulo- 
cytes decreased to the level observed with pyridoxal 
alone (not shown). These results suggest that a new 
compound, formed from pyridoxal (or pyridoxal- 
5-phosphate) and INH,is responsible for a high degree 
of iron mobilization from the cells. 
Formation ofisonicotinoyl hydrazones ofpyridoxal 
[17] and pyridoxal-5-phosphate [18] is known and is 
confirmed here by absorption spectral analysis (fig.l). 
At pH 7.4, pyridoxal has 2 maxima at A2s2 and A3~6 
and INH 1 peak at A265. Mixing of both solutions is 
accompanied by a spectral change due to the forma- 
tion of the hydrazone which has a new A 37s peak. 
When ferric citrate is added to pyridoxal isonicotinoyl 
hydrazone solution, a red-brown colour arises and an 
iron complex formation is indicated by a new 
A46s peak (fig.l)orAaTs (fig.2), respectively. Figure 3 
shows that at most, 1 tool Fe 3÷ can be bound by 
2 mol pyridoxal isonicotinoyl hydrazone. 
Table 2 provides direct evidence that pyridoxal 
isonicotinoyl hydrazone mobilizes S9Fe from reticulo- 
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Fig.1. Absorption spectra of pyridoxal isonicotinoyl hydra- 
zone (PIH), PIH-Fe 3÷ complex and individual reagents used 
for their preparation. PIH-Fe 3÷ complex contained 0.1 mM 
PIH and 0.033 mM Fe 3÷ in 50 mM Tris-HC1 buffer and 
10 mM citrate-Na 3 (pH 7.4). PIH was 0.1 raM, pyridoxal 
0.1 mM and INH 0.1 mM (all in 50 mM Tris-HC1 buffer 
(pH 7.4)), and Fe ~* 0.05 mM. The Fe 3÷ solution was prepared 
using FeC13 • 6 H:O in which the amount of iron was deter- 
mined and this solution was adjusted to pH 7.40 in the 
presence of 10 mM citrate-Na 3 and 50 mM Tris-HC1 buffer 
(pH 7 A0). Spectra were recorded against distilled water as 
blank. 
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Fig.2. Difference spectrum between P IH-Fe 3+ complex and 
pyridoxal isonicotinoyl hydrazone (PIH) and Fe 9÷ solutions. 
P IH-Fe  3÷ complex contained 0.5 mM PIH and 0.083 mM 
Fe 3÷ in 50 mM Tris-HC1 buffer, 10 mM citrate-Na 3 (pH 7.40). 
Spectrum was recorded in a 1 cm cuvette against 0.5 mM 
PIH and 0.083 mM Fe 3+ in the same buffer-citrate solution, 
each in a 1 cm cuvette. The solution of Fe 3÷ was prepared as 
in fig.1. 
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Fig.3. Formation of P IH-Fe  a÷ complex followed by increase 
A47 s . The reaction mixture contained 0.5 mM PIH, 50 mM 
Tris-HC1 buffer, 10 mM citrate-Na3 (pH 7.40) and increasing 
amounts of Fe 3+ (0.033-0.666 mM). A 475 of samples were 
measured in a 1 cm cuvette after 4 h against 0.5 mM PIH 
as blank. 
Table 2 
Effect of desferrioxamine, pyridoxal isonicotinoyl hydrazone (PIH) and P IH-Fe  3÷ 
complex on iron release from radioiron-loaded reticulocytes 
Additions Cone. Iron release % sgFe utilized for heine a
(mM) from reticulocytes synthesis during 
(%) reincubation 
Nil (control) - 1.4 -+ 0.0 60.0 -+ 0.1 
Desferrioxamine 5 3.5 -+ 0.3 39.0 -+ 0.1 
PIH 0.02 7.6 -+ 0.5 33.3 +- 2.8 
P IH-Fe  3÷ 0.02 2.3 • 0.3 28.7 +- 3.8 
PIH 0.05 24.6 -+ 1.1 34.0 -+ 1.5 
P IH-Fe  s÷ 0.05 2.7 -+ 0.4 36.9 -+ 1.0 
PIH 0.1 38.6 +- 0.5 29.3 +- 1.2 
P IH-Fe  3~ 0.1 4.1 +- 0.0 33.8 -+ 1.2 
PIH 1 66.2 ± 0.2 12.6 +- 0.2 
P IH-Fe 3. 1 6.7 +- 0.4 32.8 -+ 0.6 
a This value was obtained as in table 1 but after 60 rain reincubation 
The results are means -+ SEM of 4 samples. After 60 min preincubation with INH 
and SgFeqabeled plasma, heine radioactivity represented 12.5 -+ 1.2 of total 
cellular 59Fe. Radioiron release into the media and S9Fe utilization for heme 
synthesis were measured after 60 min reincubation of SgFeqabeled reticulocytes 
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cytes with particular efficiency; a definite effect is 
demonstrable already at 20/JM hydrazone. It should 
be pointed out that 20/2M pyridoxal isonicotinoyl 
hydrazone mobilizes twice as much iron as 5 mM 
desferrioxamine. The effects of other iron chelating 
agents (e.g., nitrilotriacetic acid, 2,2'-dipyridyl, 
2,3-dihydroxybenzoic acid, rhodotorulic acid) are 
quantitatively comparable to that of desferrioxamine. 
Iron pre-bound to pyridoxal isonicotinoyl hydrazone 
considerably decreases the mobilization of S9Fe from 
the cells (table 2). Slight iron release observed in the 
presence of P IH-Fe 3÷ complex may be due to an 
exchange of radioiron with unlabeled iron inside the 
reticulocytes. 
Reticulocytes experimentally oaded with non- 
heme radioiron appear to be a suitable assay system 
for testing the biological effectiveness of different 
iron chelating agents. 
Our preliminary results indicate that pyridoxal 
isonicotinoyl hydrazone mobilizes iron mainly from 
mitochondria of reticulocytes incubated in vitro. 
Moreover, this agent is an effective in vivo iron 
chelator able to take up iron from the hepatocyte and 
excrete it into bile (P. P., E. Negas and M. Cikrt, to be 
published). Therefore, pyridoxal isonicotinoyl 
hydrazone as a biologically effective iron chelating 
agent seems to require further investigation. 
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